OncoSec Medical Inc Beta
Cos'è Beta di OncoSec Medical Inc?
Beta di OncoSec Medical Inc è 0.00
Qual è la definizione di Beta?
BETA indica se una azione è più o meno volatile rispetto al mercato nel suo complesso. Un beta inferiore a 1 indica che la azione è meno volatile rispetto al mercato, mentre un beta più di 1 indica che la azione è più volatile. La volatilità è misurata come la fluttuazione del prezzo attorno alla media.
Beta is a measure of the risk arising from exposure to general market movements as opposed to idiosyncratic factors. The market portfolio of all investable assets has a beta of exactly 1. A beta below 1 can indicate either an investment with lower volatility than the market, or a volatile investment whose price movements are not highly correlated with the market. A beta greater than one generally means that the asset both is volatile and tends to move up and down with the market. Beta is important because it measures the risk of an investment that cannot be reduced by diversification. It does not measure the risk of an investment held on a stand-alone basis, but the amount of risk the investment adds to an already-diversified portfolio. In the capital asset pricing model, beta risk is the only kind of risk for which investors should receive an expected return higher than the risk-free rate of interest.
Beta di aziende nel Health Care settore su NASDAQ rispetto a OncoSec Medical Inc
Cosa fa OncoSec Medical Inc?
oncosec is a san diego-based biotechnology company pioneering new technologies to stimulate the body’s immune system to target and attack cancer. through our proprietary technology, we hope to deliver safer and more effective cancer treatments that can provide long-term benefits for patients. our technology, immunopulse™, is designed to enhance the local delivery and uptake of dna-based immune-targeting agents, such as il-12. clinical trials of immunopulse™ il-12 demonstrated a favorable safety profile and evidence of anti-tumor activity in the treatment of various skin cancers as well as the potential to initiate a systemic immune response. our lead program, immunopulse™ il-12, is currently in phase ii development for several indications, including metastatic melanoma, squamous cell carcinoma of the head and neck, and triple-negative breast cancer. to date, study results have laid the groundwork for the expansion into new dna-encoded therapeutic candidates and tumor indications. we ar
Aziende con beta simili a OncoSec Medical Inc
- Vision Marine Technologies ha Beta di 0.00
- Ely Gold Royalties ha Beta di 0.00
- Glacier Lake Resources ha Beta di 0.00
- Magnum Mining and Exploration ha Beta di 0.00
- Africa Opportunity Fund ha Beta di 0.00
- Fulcrum Utility Services ha Beta di 0.00
- OncoSec Medical Inc ha Beta di 0.00
- Gullewa ha Beta di 0.00
- S.A.L. Steel ha Beta di 0.00
- Andina Acquisition III ha Beta di 0.00
- Andina Acquisition III ha Beta di 0.00
- Brilliant Acquisition ha Beta di 0.00
- Indokem ha Beta di 0.00